262 results on '"Benade, Vijay"'
Search Results
2. Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist: Results from the phase 2 double-blind randomized placebo-controlled study for the treatment of excessive daytime sleepiness in adult patients with narcolepsy
3. Usmarapride (SUVN-D4010), a 5-HT4 receptor partial agonist for the potential treatment of Alzheimer's disease: Behavioural, neurochemical and pharmacological profiling
4. Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled Study
5. Safety, Tolerability, and Pharmacokinetics of Ropanicant (SUVN-911), a Novel Alpha4 Beta2 Nicotinic Acetylcholine Receptor (α4β2 nAChR) Antagonist, in Healthy Adult and Elderly Subjects
6. Hits and misses with animal models of narcolepsy and the implications for drug discovery
7. Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation
8. Masupirdine (SUVN‐502) for the Potential Treatment of Agitation in Patients with Dementia of the Alzheimer’s Type: Preliminary Efficacy and Phase‐3 Study Design
9. Mechanistic evaluation of tapentadol in reducing the pain perception using in-vivo brain and spinal cord microdialysis in rats
10. 0609 Samelisant, Histamine 3 Receptor Agonist for the Potential Treatment of Excessive Daytime Sleepiness in Patients with Narcolepsy
11. 0051 Samelisant, a H3 Receptor Inverse Agonist for the Potential Treatment of Excessive Daytime Sleepiness in Parkinson’s Disease
12. Concurrent administration of atypical antipsychotics and donepezil: drug interaction study in rats
13. SUVN-502, a novel, potent, pure, and orally active 5-HT6 receptor antagonist: pharmacological, behavioral, and neurochemical characterization
14. Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders
15. Synthesis and SAR of Imidazo[1,5-a]pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's disease
16. Effects of Masupirdine (SUVN‐502) on Agitation/Aggression and Psychosis in Patients with Probable Alzheimer’s Disease: A Post Hoc Analysis
17. Effect of Concurrent Use of Memantine on The Efficacy of Masupirdine (SUVN‐502): A Post‐hoc Analysis of a Phase‐2 Randomized Placebo‐Controlled Study
18. Potential beneficial effects of masupirdine (SUVN‐502) on agitation/aggression and psychosis in patients with moderate Alzheimer's disease: Exploratory post hoc analyses
19. A sensitive and selective quantification of catecholamine neurotransmitters in rat microdialysates by pre-column dansyl chloride derivatization using liquid chromatography–tandem mass spectrometry
20. Simultaneous monitoring of electroencephalographic characteristics in animals subjected to behavioral tests: a preclinical investigation
21. Approach to reduce the non-specific binding in microdialysis
22. Difference in the norepinephrine levels of experimental and non-experimental rats with age in the object recognition task
23. 0265 Samelisant (SUVN-G3031), a Histamine H3 Receptor Inverse Agonist in Animal Models of Narcolepsy
24. 0624 Samelisant (SUVN-G3031), Baseline Characteristics from a Phase-2 Study Evaluating Efficacy and Safety in Patients with Narcolepsy
25. Masupirdine (SUVN-502), A Serotonin Receptor Sub-Type 6 Antagonist for the Potential Treatment of Agitation and Psychosis in Patients with Dementia of Alzheimer’s Type (P1-1.Virtual)
26. Effect of masupirdine (SUVN‐502) on cognition in patients with moderate Alzheimer's disease: A randomized, double‐blind, phase 2, proof‐of‐concept study
27. Effect of Age, Cognitive Impairment Severity, and Duration of Disease on Efficacy of Masupirdine in Moderate Alzheimer's Disease Patients: A Post Hoc Analysis of a Phase-2 Randomized Placebo Controlled Study Results
28. Chronic treatment with a selective 5-HT6 receptor antagonist alters the behavioral and neurochemical effects of ethanol in young adult rats
29. Modulation of the cyclooxygenase pathway via inhibition of nitric oxide production contributes to the anti-inflammatory activity of kaempferol
30. Metformin, a calorie restriction mimetic for the treatment of Alzheimer’s disease: A preclinical investigation
31. Masupirdine (SUVN‐502): A promising clinical candidate for the management of agitation in Alzheimer’s dementia
32. 1‐[2‐(1‐Cyclobutylpiperidin‐4‐yloxy)‐6,7‐dihydro‐4 H ‐thiazolo[5,4‐ c ]pyridin‐5‐yl]propan‐1‐one: a Histamine H 3 Receptor Inverse Agonist with Efficacy in Animal Models of Cognition
33. A simple and rapid method to collect the cerebrospinal fluid of rats and its application for the assessment of drug penetration into the central nervous system
34. Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT4Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer’s Disease
35. Concurrent administration of atypical antipsychotics and donepezil: drug interaction study in rats
36. 506 Samelisant: Baseline Characteristics from a Phase 2 Study Evaluating Efficacy and Safety in Patients with Narcolepsy
37. 004 Samelisant (SUVN-G3031), Differentiating features over current treatments of narcolepsy
38. Histamine 3 receptor inverse agonist Samelisant (SUVN-G3031): Pharmacological characterization of an investigational agent for the treatment of cognitive disorders
39. LC–MS/MS method for the quantification of almotriptan in dialysates: Application to rat brain and blood microdialysis study
40. Masupirdine (SUVN‐502) in combination with donepezil and memantine in moderate Alzheimer's disease: Effect of AD duration since diagnosis and patient’s age on efficacy endpoints
41. Masupirdine (SUVN‐502): Novel treatment option for the management of behavioral and psychological symptoms in patients with Alzheimer’s disease
42. 1‐[2‐(1‐Cyclobutylpiperidin‐4‐yloxy)‐6,7‐dihydro‐4H‐thiazolo[5,4‐c]pyridin‐5‐yl]propan‐1‐one: a Histamine H3 Receptor Inverse Agonist with Efficacy in Animal Models of Cognition
43. 0649 Samelisant Improves the Symptoms of Excessive Daytime Sleepiness in Narcolepsy: Results from a Phase-2 Study
44. P3-042: SUVN-502: A PURE 5-HT6 ANTAGONIST POTENTIATES THE EFFECTS OF DONEPEZIL OR MEMANTINE IN ANIMAL MODELS OF COGNITION, NEUROCHEMISTRY AND ELECTROPHYSIOLOGY
45. P1-089: SUVN-502 + DONEPEZIL + MEMANTINE (TRIPLE COMBINATION): FIRST-IN-CLASS AND A PROMISING NEW APPROACH FOR THE SYMPTOMATIC TREATMENT OF ALZHEIMER'S DISEASE DEMENTIA
46. 0054 SUVN-G3031, a Histamine H3 Receptor Inverse Agonist Produces Wake Promoting Effect in Orexin-2-saporin Lesioned Rats
47. Discovery and Development of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide Dihydrochloride (SUVN-G3031): A Novel, Potent, Selective, and Orally Active Histamine H3 Receptor Inverse Agonist with Robust Wake-Promoting Activity
48. 1021 Samelisant: Clinician and Patient Global Impression from a Double-Blind, Phase-2 Study in Patients with Narcolepsy
49. P3‐273: NEUROCHEMICAL AND ELECTROPHYSIOLOGICAL CHARACTERIZATION OF SUVN‐I6107, A NOVEL MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATOR
50. P2‐234: CORRELATION OF NEUROTRANSMITTER MODULATIONS AND NEURONAL OSCILLATIONS IN RAT BRAIN
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.